IGF1 and early-onset autosomal dominant Alzheimer disease: Trofinetide’s classification as “Speculative” despite achieving the highest peptide ranking reflects a complete absence of Alzheimer’s-disease-specific experimental data, with therapeutic hypothesis derived exclusively from network proximity to IGF1 pathway genes, without mechanistic confirmation or demonstration of efficacy in transgenic AD mice.